References
- Melton LJ III. How many women have osteoporosis now? J. Bone Miner Res. 10, 175–177 (1995).
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285, 785–795 (2001).
- Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic factures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner Res. 12,24-35 (1997).
- Hoerger TJ, Downs KE, Lakshmanan MC et aL Healthcare use among US women aged 45 and older: total costs and costs for selected postmenopausal health risks. Women.'s Health Gender-Based Med. 8, 1077–1089 (1999).
- Stafford R, Drieling R, Hersh A. National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch. Intern. Med. 164,1525-1530 (2004).
- Fleurence R, Torgerson DJ, Reid DM. Cost-effectiveness of hormone replacement therapy for fracture prevention in young postmenopausal women: an economic analysis based on a prospective cohort study. Osteoporosis Int. 12,637–643 (2002).
- Zethraeus N, Ben Sedrine W, Caulin F et aL Models for assessing the cost-effectivness of the treatment and prevention of osteoporosis. Osteoporosis Int. 13,841–857 (2002).
- ••One of the most recent published literature reviews; most of the studies reviewed evaluate the use of hormone therapy for osteoporosis.
- Tosteson ANA, Jonsson B, Grima DT et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporosis Int. 12,849–857 (2001).
- ••Comprehensive summary of conceptualissues in osteoporosis cost-effectiveness models.
- Maricic M, Adachi JD, Sarkar S et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch. Intern. Med. 162, 1140–1143 (2002).
- Miller P Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis. Southern Med. J. 96(5), 478–485 (2003).
- Harris Si', Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282, 1344–1352 (1999).
- Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348,1535–1541 (1996).
- Chestnut C, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am. I Med. 109,267–276 (2000).
- Cummings SR, Black DM, Thompson D et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280,2077–2082 (1998).
- Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282, 637–645 (1999).
- Neer RM, Arnaud CD, Zanchetta JR et al Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N EngL J. Med. 344(19), 1434–1441 (2001).
- Melton LJ III, Gabriel SE, Crowson CS et al. Cost-equivalence of different osteoporotic fractures. Osteoporosis Int. 14, 383–388 (2003).
- Ethgen O, Tellier V, Sedrine WB et al. Health-related quality of life and cost of ambulatory care in osteoporosis: how may such outcome measures be valuable information to health decision makers and payers? Bone 32,718–724 (2003).
- Gavin NI, Ohsfeldt RL, Thorp JM. Determinants of hormone replacement therapy duration among postmenopausal women with intact uteri. Menopause 8, 377–383 (2001).
- Kayser J, Ettinger B, Pressman A. Postmenopausal hormone support: Discontinuation of raloxifene versus estrogen. Menopause 8,328–332 (2001).
- Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. 10, 601–615 (2001).
- Office of Technology Assessment (OTA). Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy Government Printing Office, Washington DC, USA (1995).
- Armstrong K, Chen T-M, Albert D et al. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet. GynecoL 98,996–1003 (2001).
- Mullins CD, Ohsfeldt RL. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J. Managed Care Pharm. 9,150–158 (2003).
- Kanis JA, Johnell O, Oden A et aL Intervention thresholds for osteoporosis. Bone31, 26–31 (2002).
- Lindsay R, Silverman SL, Cooper C et aL Risk of a new vertebral fracture in the year following a fracture. JAMA 285,320–323 (2001).
- •Highlights the potential value of treatment intervention prior to the first fracture.
- Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in health postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002).
- Blakely JA. The Heart and Estrogen/progestin Replacement Study revisited: hormone replacement therapy produced net harm, consistent with the observational data. Arch. Intern. Med. 160, 2897–2900 (2000).
- Cost-Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA (1996).
- Watts NB. Bisphosphonate treatment of osteoporosis. Clin. Geriatric Med. 19, 395–414 (2003).
- United States Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann. Intern. Med. 137, 834–839 (2002).
- Cranney A, Guyatt G, Griffith L et aL, the Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Rev 23,570–578 (2002).
- Cummings SR, Palermo L, Browner W et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 283, 1318–1321 (2000).
- Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N EngL J Med. 337,1641–1647 (1997).
- Cummings SR, Eckert S, Krueger KA et aL The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281,2189–2197 (1999).
- Cauley J, Norton L, Lippman M et aL Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treatment 65, 125–134 (2001).
- Lippman ME, Krueger KA, Eckert S et aL Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the Multiple Outcomes of Raloxifene Evaluation study participants. J. Clin. OncoL 19,3111–3116 (2001).
- Cummings SR, Duong T, Kenyon E et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287,216–220 (2002).
- Walsh BW, Kuller LH, Wild RA et aL Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279, 1445–1451 (1998).
- Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: 4-year results from the MORE randomized trial. JAMA 287,847–857 (2002).
- Ettinger B, Pressman A, Schein J et aL Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am. J Man. Care 4, 1377–1382 (1998).
- National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int. 8\(Suppl. 4), S1—S88 (1998).
- Kanis JA, Brazier JE, Stevenson M et al. Treatment of established osteoporosis: A systematic review and cost-utility analysis. Health Technology Assess. 6(29), 1–253 (2002).
- Stevenson MD, Oakley J, Chilcott JB. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med. Decis. Making 24,89–100 (2004).
- Coyle D, Cranney A, Lee KM et aL Cost- effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. PharmacoEconomics 19,565–575 (2001).
- Johnell O, Jonsson B, Jonsson L et aL Cost effectiveness of alendronate (Fosamaxe) for the treatment of osteoporosis and prevention of fractures. PharmacoEconomics 21(5), 305–314 (2003).
- Iglesias CP, Torgerson DJ, Bearne A et aL The cost utility of bisphosphonate treatment in established osteoporosis. Q. J Med. 95,305–311 (2002).
- Sins E, Chen Y-T, Abbott T et aL Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch. Intern. Med. 164, 1108–1112 (2004).
- Miller P, Barlas S, Brenneman S et aL An approach to identifying osteopenic women at increased short-term risk of fracture. Arch. Intern. Med. 164,1113–1120 (2004).
- Pressman A, Forsyth B, Ettinger B et al. Initiation of osteoporosis treatment after bone mineral density testing. Osteoporosis Int. 12,337–342 (2001).
- Cram P, Rosenthal GE, Ohsfeldt RL et al. Failure to recognize and act on abnormal test results: The case of screening bone densitometry. Joint Commission J. Quality Safety (2005) (In Press).
- Cuddihy M-T, Gabriel S, Crowson C et aL Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch. Intern. Med. 162,421–426 (2002).
- Tosteson ANA, Grove MR, Hammond CS et al. Early discontinuation of treatment for osteoporosis. Am. J Med. 115,209–216 (2003).
- Biskobing DM. Novel therapies for osteoporosis. Expert Opin. Investigational Drugs 12,611–621 (2004).
- Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl. Med. 350,459–468 (2003).
Websites
- Centers for Disease Control, National Center for Health Statistics, National Health and Nutritional Examination Survey. Osteoporosis www.cdc.gov/nchs/data/nhanes/databriefs/ osteoporosis.pdf (Accessed November 2004)
- World Health Organization. The burden of musculoskeletal conditions at the start of the new millennium. WHO Technical Report Series 919, http://whqlibdoc.who.inthrs/ WHO_TRS_919.pdf (Accessed November 2004)
- United States Census Bureau. Table 2a. Projected population in the United States, by age and sex: 2000 to 2050 www.census.gov a(Accessed November 2004)
- National Institute for Clinical Excellence. The Clinical Effectiveness' and Cost Effectiveness of Prevention and Treatment of Osteoporosis (with addenda). December 2003 www.nice.org.uk/pdf/Assessment_report_ost eo.pdf (Accessed November 2004) Second addendum, March 2004 www.nice.org.uk/page.aspx?o = 115309 (Accessed November 2004) Best single resource for information about fracture risk, treatment effectiveness and costs, although much of it is specific to the UK.